Estimating Survival in Patients with Operable Skeletal Metastases: An Application of a Bayesian Belief Network by Forsberg, Jonathan Agner et al.
Estimating Survival in Patients with Operable Skeletal
Metastases: An Application of a Bayesian Belief Network
Jonathan Agner Forsberg
1,2*, John Eberhardt
3, Patrick J. Boland
1, Rikard Wedin
2, John H. Healey
1
1Orthopaedic Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York, United States of America, 2Section of Orthopaedics and
Sports Medicine, Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, 3Bioinformatics Division,
DecisionQ Corporation, Washington, D.C., United States of America
Abstract
Background: Accurate estimations of life expectancy are important in the management of patients with metastatic cancer
affecting the extremities, and help set patient, family, and physician expectations. Clinically, the decision whether to operate
on patients with skeletal metastases, as well as the choice of surgical procedure, are predicated on an individual patient’s
estimated survival. Currently, there are no reliable methods for estimating survival in this patient population. Bayesian
classification, which includes Bayesian belief network (BBN) modeling, is a statistical method that explores conditional,
probabilistic relationships between variables to estimate the likelihood of an outcome using observed data. Thus, BBN
models are being used with increasing frequency in a variety of diagnoses to codify complex clinical data into prognostic
models. The purpose of this study was to determine the feasibility of developing Bayesian classifiers to estimate survival in
patients undergoing surgery for metastases of the axial and appendicular skeleton.
Methods: We searched an institution-owned patient management database for all patients who underwent surgery for
skeletal metastases between 1999 and 2003. We then developed and trained a machine-learned BBN model to estimate
survival in months using candidate features based on historical data. Ten-fold cross-validation and receiver operating
characteristic (ROC) curve analysis were performed to evaluate the BNN model’s accuracy and robustness.
Results: A total of 189 consecutive patients were included. First-degree predictors of survival differed between the 3-month
and 12-month models. Following cross validation, the area under the ROC curve was 0.85 (95% CI: 0.80–0.93) for 3-month
probability of survival and 0.83 (95% CI: 0.77–0.90) for 12-month probability of survival.
Conclusions: A robust, accurate, probabilistic naı ¨ve BBN model was successfully developed using observed clinical data to
estimate individualized survival in patients with operable skeletal metastases. This method warrants further development
and must be externally validated in other patient populations.
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Introduction
‘‘Doc, how long have I got?’’ For the physician, such questions
related to life expectancy are among the most difficult to answer.
An accurate estimation of survival is important, however, and can
help set patient, family, and physician expectations. Clinically, the
decision to operate on patients with skeletal metastases of the
extremities, as well as the choice of surgical procedure, is
predicated on a patient’s estimated survival [1]. The goal of
surgery in this setting is not to cure the disease, but to relieve pain
and optimize functional mobility for the maximum amount of
time. Thus, a considerable amount of effort has been spent
identifying useful prognosticators for use in the metastatic setting.
Several independent predictors of survival have been identified
for patients with metastatic bone disease of the extremities [2–8].
These include the primary oncologic diagnosis, Eastern Cooper-
ative Oncology Group (ECOG) performance status score [9];
number of bone metastases, presence of visceral metastases, serum
hemoglobin level, senior surgeon’s estimate of survival [6];
appendicular, as opposed to axial, bone metastases [10]; and type
of reconstructive procedure performed [5]. Although many
prognostic factors are known, the predictability of survival in
patients with metastatic bone disease remains alarmingly low—
only 5–15% in the best-reported series [6]. Relationships between
prognostic variables are difficult to interpret, and better means of
prognostication are needed since there are currently no reliable
methods for estimating survival in this patient population.
Bayesian classification, which includes Bayesian belief network
(BBN) modeling, is a statistical method that represents conditional,
probabilistic relationships between variables, or ‘‘features.’’ Once
described, these relationships enable the development of a
graphical n-dimensional structure, or model, which codifies all
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network. Bayesian classification also accounts effectively for data
multi-dimensionality and uncertainty—a quality that enables BBN
models to maintain their robustness in the context of incomplete or
discordant clinical data. As such, BBNs have been successfully
used to both model complex relationships, as well as to classify
outcomes, in a variety of oncologic diagnoses [11–20]. The
purpose of this study was to determine the feasibility of developing
and training Bayesian classifiers designed to estimate survival in
patients undergoing surgery for skeletal metastases involving the
axial and appendicular skeleton.
Methods
After obtaining approval from the institutional review board of
Memorial Sloan-Kettering Cancer Center, who issued a waiver of
informed consent, we searched the institution-owned patient
management database (Disease Management System, v.5.2, 1996;
MSKCC) for all patients who underwent surgery for metastatic
bone disease between 1999 and 2003. For each patient, we
reviewed his or her medical records and imaging studies. These
data, along with several other features, were used to construct the
BBN model.
Fifteen candidate features were chosen based on their current
clinical or historical association with survival in patients with
operatively treated skeletal metastases. These included the follow-
ing: age at the time of surgery, race, sex, estimated glomerular
filtration rate (mL/min/1.73 m
2), serum calcium concentration
(mg/dL), serum albumin concentration (g/dL), indication for
surgery (impending or completed pathologic fracture), number of
bone metastases (solitary or multiple), surgeon’s estimate of survival
(postoperatively, in months), presence or absence of visceral
metastases, presence or absence of lymph node metastases, prior
chemotherapy (yes or no), preoperative hemoglobin (mg/dL, on
admission, prior to transfusion, if applicable), absolute lymphocyte
count (K/mL), and the primary oncologic diagnosis. The oncologic
diagnosis was classified into three groups according to the method
described by Katagiri et al. [21], but with some modifications.
Briefly, breast, prostate, renal cell, and thyroid carcinoma, multiple
myeloma, and malignant lymphoma were included in Group 3;
sarcomas and other carcinomas were included in Group 2; and
lung, gastric, and hepatocellular carcinoma and melanoma were
included in Group 1.
The following definitions were used in this study. An impending
pathologic fracture was one in which the degree of bone and/or
cortical disruption warranted, in the opinion of the treating surgeon
(PJB or JHH), prophylactic surgical stabilization to prevent fracture.
A completed pathologic fracture was one in which a cortical lesion
had caused a change in bone length, alignment, rotation, or loss of
height as determined by imaging. The surgeon’s estimate of survival
was made preoperatively by the treating surgeon (PJB or JHH) after
reviewing the patients’ medical records and imaging studies,
obtained a complete medical history, and performed a thorough
physical examination. Biopsy-proven or clinically obvious metasta-
ses to organs within the chest or abdomen were considered visceral
metastases. Only biopsy-provenmetastases to the lymph nodes were
considered indicative of lymph node involvement. Finally, a patient
was considered as having undergone prior chemotherapy, if he or
she had received any chemotherapy at any time for the current,
active oncologic diagnosis.
Conventional Statistical Analysis
Conventional statistical analysis was performed using SAS
software (v.9.2, SAS Institute Inc., Cary, NC, USA). Since we
modified a previously described diagnosis grouping method,
overall survival of patients in each diagnosis group was compared
using the Kaplan-Meier method with log-rank assessment.
Bayesian Statistical Analysis and Model Development
The BBN models were developed using commercially available
machine-learning algorithms (FasterAnalytics, DecisionQ, Wash-
ington, DC, USA) that automatically learn network structures and
joint probabilities from the training data.
The training data set included all cases identified from the
patient management database during the study period. All 15
candidate features were considered. Features containing continu-
ous variables were converted into categorical variables by equal-
area binning based on prior distributions. The machine-learning
algorithm uses a scoring formula that balances goodness-of-fit
against robustness using a parsimony metric to reduce the risk of
overfitting the final model to the training data set. To refine the
model, we used a step-wise training process. Quantitative and
qualitative assessments were used to optimize variable preparation
and selection. Unrelated and confounding features were then
pruned from the preliminary models to produce the final models.
We trained the BBN to specify network structure and prior
probability distributions to develop classifiers of estimated survival
at 3 and 12 months, which we consider to be useful discriminators
for surgical decision-making. We trained a separate classifier for
each outcome measure (survival .3 months and survival .12
months) because, as a parametric modeling methodology, BBNs
are not well suited to provide discrete estimates in time. Also,
training two separate models eliminates the possibility of outcome
measures acting as confounding features within the same BBN.
Because BBN models are directed graphs of conditional
dependence, the network structure can be portrayed graphically
to illustrate the conditional interdependence of the features. First-
degree predictors are defined as those nodes that share edges with
the outcome of interest, while second-degree predictors are those
nodes that share edges with the first-degree predictors. Inference
tables were calculated for both models depicting posterior
estimates of probability for each possible permutation and the
expected outcome, survival greater than 3 months and 12 months,
respectively.
Internal Validation
Ten-fold cross-validation was performed to assess the robustness
of the final 3-month and 12-month models. Data were randomized
and divided into 10 matching train-and-test sets. Each train-and-
test set consisted of a training set composed of 90% of patient
records and a test set composed of the remaining 10% of records.
Each matching set was unique, and there was no overlap between
the independent test sets. A BBN model was trained, using each
training set, by applying the same parameters as the final models,
then tested on the corresponding test set. A receiver operating
characteristic (ROC) curve was plotted for each test to evaluate the
classifier’s accuracy and the model’s robustness. The ROC curve is
a graphical plot of sensitivity vs. 1-specificity at all discrimination
threshold levels. The area under the ROC curve (AUC) was then
calculated for each BBN model to assess its overall accuracy and
robustness.
Results
A total of 189 consecutive patients were identified and, thus,
used for this analysis. Median follow-up was 8 months (inter-
quartile range [IQR] 2, 22), which was adequate for determining
overall survival up to and including either the 3-month or 12-
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(54, 72). Most patients were women (55.1%), and most were white,
non-Hispanic (85.2%). Most patients also had visceral metastases
(60.3%), multiple bone metastases (71.0%), and prior systemic
therapy (56.1%). A few patients had lymph node involvement
(18.8%). When classified according to diagnosis group, most
patients were in Group 3 (54.5%), followed by Group 1 (27.2%),
and then Group 2 (18.2%). Regarding overall survival (Fig. 1), 58
patients (30.7%) survived less than 3 months, 53 (28.0%) survived
3–12 months, and 78 (41.3%) survived more than 12 months.
Baseline (posterior) distributions represented as proportions are
depicted in Fig. 2.
The features comprising the final models are described in
Table 1. First-degree predictors differed between the two models.
In the 3-month model (Fig. 2), the surgeon’s estimate of survival,
hemoglobin concentration, absolute lymphocyte count, completed
pathologic fracture, and ECOG performance status were first-
degree predictors of survival. In the 12-month model (Fig. 3), only
Figure 1. Kaplan-Meier curves showing overall survival for patients by diagnosis group. The overall survival of patients in Group 1 was
significantly lower than that of patients in Groups 2 and 3 at the 3-month time point
‘ (p,0.0001, log-rank test). Overall survival was significantly
different between all groups at the 12-month time point* (p,0.0001, log-rank test).
doi:10.1371/journal.pone.0019956.g001
Figure 2. Three-month BBN model with posterior distributions depicted as proportions (%) of the training population. As shown,
there are five first-degree predictors of 3-month survival: the surgeon’s estimate of survival (‘‘surgeon_estimate_of_survival’’), preoperative
hemoglobin concentration (‘‘hemoglobin’’), preoperative absolute lymphocyte count (‘‘absolute_lymphocyte_count’’), ECOG performance status
(‘‘ECOG’’), and the presence of a completed pathologic fracture (‘‘completed_path_fx’’). The network structure indicates that the primary oncologic
diagnosis (‘‘dx_grouping’’) and the presence of visceral metastases (‘‘visceral_mets’’) are both first-degree associates of the surgeon’s estimate node.
doi:10.1371/journal.pone.0019956.g002
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number of bone metastases, and the diagnosis group were first-
degree predictors of survival. In the 3-month model, the diagnosis
group and the presence of visceral metastases were first-degree
associates of the surgeon’s estimate node. In contrast, in the
12-month model, ECOG performance status and presence of
visceral metastases were first-degree associates of the surgeon’s
estimate node.
Cross-validation ROC curve analysis showed that both the 3-
month and 12-month models were robust. Mean AUC for 3-
Figure 3. Twelve-month BBN model. As shown, there are four first-degree predictors of 12-month survival: the surgeon’s estimate of survival
(‘‘surgeon_estimate_of_survival’’), preoperative hemoglobin concentration (‘‘hemoglobin’’), the number of bone metastases (‘‘bone_mets’’), and the
primary oncologic diagnosis (‘‘dx_grouping’’). In contrast to the 3-month model, the network structure of the 12-month model indicates that the
ECOG performance status (‘‘ECOG’’) and the presence of visceral metastases (visceral_mets) are both first-degree associates of the surgeon’s estimate
node.
doi:10.1371/journal.pone.0019956.g003
Table 1. Network features used in the final BBN models.
Feature Model Label Description Node States
Survival .12 months survival_greater_than_1year Overall survival exceeding 12 months yes, no
Survival .3 months survival_greater_than_3mos Overall survival exceeding 3 months yes, no
Surgeon’s estimate of survival surgeon_estimate_of_survival The senior surgeon’s estimate of survival
(in months) after obtaining
the patient’s history, reviewing his or
her laboratory and imaging results,
and performing a thorough physical
examination
,4, 4–9, 9–18, .18
Oncologic diagnosis grouping dx_grouping Primary oncologic diagnosis, grouped
as follows:
1: lung, hepatocellular, and gastric
carcinoma; melanoma
2: sarcoma and other carcinoma, not
in Groups 1 or 3
3: breast, prostate, thyroid, and renal
cell carcinoma; myeloma; lymphoma
1, 2, 3
ECOG performance status ECOG Eastern Cooperative Oncology Group
performance status, assessed
preoperatively by treating physician
#2, $3
Pathologic fracture status completed_path_fx Indicates whether surgery was
performed for an impending or
completed pathologic fracture
yes, no
Skeletal metastases bone_mets Indicates whether the patient had
solitary or multiple skeletal metastases
solitary, multiple
Organ metastases visceral_mets Presence of metastases to visceral
organs, lungs, or brain
yes, no
Lymph node metastases nodal_involvement Presence of lymph node metastases yes, no
Sex sex Patient sex male, female
Hemoglobin concentration hemoglobin Preoperative hemoglobin concentration
(in mg/dL), prior to blood transfusion,
if applicable
,10.1, 10.1–11.4
11.4–12.9, .12.9
Absolute lymphocyte count absolute_lymphocyte_count Preoperative absolute lymphocyte
count (in mg/dL), prior to transfusion,
if applicable
,0.6, 0.6–1.1, 1.1–1.6,
.1.6
Features included in the final BBN models. Each feature, its label, description, and possible node states are shown. Continuous variables are represented as categorical
variables.
doi:10.1371/journal.pone.0019956.t001
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mean AUC for 12-month probability of survival was 0.83 (95%
CI: 0.77–0.90). Inference tables were calculated for 3-month
survival (Table 2) and 12-month survival (Table 3). Posterior
estimates of probability of 3-month survival ranged from 0.8–
96.7%, while posterior estimates of probability of 12-month
survival ranged from 0.9–99.2%. In each case, we used the
estimated case frequency to select the ten most likely inferential
cases, since there were 256 and 128 potential permutations for the
3- and 12-month models respectively.
Discussion
Because predictive models permitting individualized estimation
of survival are lacking, we trained two full machine-learned BBN
models, using observed clinical data, to estimate survival in
patients with operable skeletal metastases. These models were
shown to be robust on ten-fold cross-validation. We also
characterized the importance of the surgeon’s estimate of survival,
and we believe that it should be included in future iterations of this
model, whenever possible. However, if the surgeon’s estimate is
not included, ECOG performance status, the oncologic diagnosis
group, and the presence of visceral metastases may be used to
estimate this important subjective feature.
In the present analysis, we used the 3-month and 12-month time
points, since we consider them to be useful discriminators for
surgical decision-making. We believe that survival less than 3
months is a relative contraindication to surgical management of
certain impending pathologic fractures, particularly those in the
upper extremity. If surgical stabilization is deemed to be necessary,
shorter life expectancies (3–12 months) are thought to warrant less-
invasive stabilization procedures that do not require prolonged
rehabilitation periods. On the other hand, longer life expectancies
($12 months) warrant more-durable reconstruction procedures,
which are associated with significant operative morbidity and
longer rehabilitation times. Thus, less-invasive stabilization
techniques may be appropriate for patients with an estimated
survival of less than 12 months, while more-durable reconstruction
options may be considered for those with an estimated survival
longer than 12 months. These concepts and the surgical
techniques are described elsewhere [22].
Unfortunately, although modeling and, thus, estimating survival
in patients with metastatic disease is important in the surgical
management of these patients, it has proven to be challenging
[2,5,6,8]. For instance, there is no consensus regarding which
variables should be included in survival estimation models. In an
attempt to codify several known independent predictors of
survival, Nathan et al. developed a conventional, regression-
derived nomogram based on 191 patients with operable skeletal
metastases [6]. Variables, collected prospectively, included ECOG
performance status, number of bone metastases, presence of
visceral metastases, and serum hemoglobin concentration. Eval-
uation in a five-patient test set yielded an accurate survival
estimate in two patients, but this method has not yet been
internally or externally validated.
A closer look at Nathan et al.’s results gives us some insight into
the challenges inherent to predicting survival in these patients [6].
Linear regression analysis revealed that, in terms of accuracy, the
‘‘attending surgeon’s [subjective] prediction’’ of survival was
superior to any other covariate included in their analysis. The
authors attributed this finding to the attending surgeon’s extensive
experience in the field, but no further conclusions were drawn.
Other studies, including a systematic review of physicians’ survival
predictions, also emphasize subjective assessments and cite the
importance of the physician’s role in estimating patient survival
[23–25].
In the context of the current study, what makes the surgeon’s
estimate of survival so important? Clearly, an estimate of survival
is made after reviewing the patient’s medical records and imaging
studies and performing a thorough physical examination on the
patient. Some variables considered by the surgeon are objective
and thus quantifiable, such as ECOG performance scores,
laboratory results, and radiographic findings. However, others
are subjective and thus not quantifiable, such as the patient’s
appearance of sickness, the patient’s demeanor, and the surgeon’s
‘‘gut feeling’’ following the consultation. These subjective
observations are unlikely to be useful as individual covariates in
the traditional sense, but we believe that they are contained within
Table 2. Posterior estimates of survival at 3 months (10 most frequent cases).
Drivers Target
Expected
frequency ECOG
Absolute
lymphocyte
count (K/mL)
Completed
Pathologic
Fracture
Hemoglobin
concentration
(mg/dL)
Surgeon’s estimate
of survival (months)
Probability of
survival .3 months
No Yes
2.02% $3 ,0.6 Yes ,10.1 ,4 96.7 3.3
1.33% $3 ,0.6 No ,10.1 ,4 91.1 8.9
1.73% $3 ,0.6 Yes 10.1–11.4 ,4 95.3 4.7
1.17% $3 ,0.6 No 10.1–11.4 ,4 87.6 12.4
1.09% $3 0.6–1.1 Yes ,10.1 ,4 94.8 5.2
0.95% $3 0.6–1.1 Yes 10.1–11.4 ,4 92.7 7.3
0.90% #2 ,0.6 Yes ,10.1 ,4 89.5 10.5
0.87% $3 ,0.6 Yes 11.4–12.9 ,4 86.5 13.5
0.81% #2 1.1–1.6 No .12.9 4–9 0.8 99.2
0.80% #2 ,0.6 Yes 10.1–11.4 ,4 85.6 14.4
The 3-month posterior estimates of survival characterizing the data set by most- to least-frequent cases. The ten most likely cases were selected from 256 possible
permutations.
doi:10.1371/journal.pone.0019956.t002
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degree predictor in both survival models (Figs. 2 and 3).
Historically, the physician’s assessment appears to be important
when estimating survival [6,23–25], and if the subjective
observations listed above are indeed represented by the surgeon’s
estimate, the results of the present study support this claim.
Fortunately, the BBN method may help us to better understand
the complex relationships that exist between objective and
subjective features. The hierarchy of conditional dependence,
identified by the BBN, defines how individual features known to be
associated with survival relate to one another. When graphically
displayed, the network structure depicts these relationships. For
example, we found that the surgeon’s estimate is a first-degree
predictor of overall survival at both 3 months and 12 months.
However, the nodes associated with the surgeon’s estimate differed
between the models. In the 3-month model, the oncologic
diagnosis group and the presence of visceral metastases were
first-degree associates of the surgeon’s estimate node. In contrast,
in the 12-month model, ECOG performance status and the
presence of visceral metastases were first-degree associates. This
suggests that in short-term survivors, represented by the 3-month
model, specific oncologic diagnosis and the presence of visceral
metastases are most influential in the development of a survival
estimate by the senior surgeon, while in longer-term survivors,
represented by the 12-month model, ECOG performance status
and the presence of visceral metastases are most important in the
development of the surgeon’s estimate of survival. Other features,
such as the number of bone metastases, hemoglobin concentra-
tion, absolute lymphocyte count, and completed pathologic
fracture, may also inform the surgeon’s estimate, but they have
significant prognostic value of their own, as shown in both model
structures (Figs. 2 and 3). This is further supported by the
observation that a BBN model that included the surgeon’s estimate
and these independent factors (the number of bone metastases,
hemoglobin concentration, absolute lymphocyte count, and
completed pathologic fracture) outperformed a BBN model
containing the surgeon’s estimate alone (data not shown).
Nevertheless, in order to capture the subjective, yet important,
elements of the clinical evaluation, we believe that future
predictive models designed to estimate survival in patients with
operatively treated skeletal metastases should include a surgeon’s
estimate of survival.
This cohort of surgically treated patients with metastatic disease
involving the axial and appendicular skeleton is among the largest
reported in the literature [1,5,6,10,21]. As such, it is well suited for
prognostic model development. Nevertheless, the limitations of
this study are those inherent to a feasibility study. No comparisons
were made to existing models or nomograms, and no external
validation was performed. Validation of these models in an
independent data set followed by an appropriate comparison to
existing models is the next logical step in the evaluation of this
method. The ultimate goal being to provide an accurate,
personalized answer to the difficult question, ‘‘Doc, how long
have I got?’’
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